LLY compared with ABUS: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

ABUSArbutus Biopharma Corp

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

ABUSArbutus Biopharma Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only ABUS 9

MRNAModernacustomer

ALNYAlnylam Pharmaceuticalscustomer

ASMBAssembly Biosciencessupplier

—Qilu Pharmaceuticalunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

customer

5 more · ABUS chain ›

LLYELI Lilly & Co

1,379.52▼−2.71%

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

ABUSArbutus Biopharma Corp

3.75▼−7.64%

Regular sessionNov 5 '26

Mkt cap$803.3MRevenue$1MQ2 FY26Revenue$14MFY25

Compare

Regular sessionNov 5 '26

LLYELI Lilly & Co

ABUSArbutus Biopharma Corp

1,379.52▼−2.71%

Price

3.75▼−7.64%

$1.3T

Mkt cap

$803.3M

Q3 FY26$24.4B

Revenue

$1MQ2 FY26

FY25$65.2B

Revenue

$14MFY25

LLY1,379.52▼−2.71%vsABUS3.75▼−7.64%Regular sessionNov 5 '26